Methylated markers for colorectal cancer

Patent metadata

Field	Value
Publication number	US-11486007-B2
Application number	US-201515315874-A
Country	US
Kind code	B2
Filing date	Jun 3, 2015
Priority date	Jun 4, 2014
Publication date	Nov 1, 2022
Grant date	Nov 1, 2022

Abstract

Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.

First claim

What is claimed is:

1. A detection method comprising:
a) treating DNA from a cell free biological sample obtained from a subject having or suspected of having a colorectal neoplasm with one or more reagents that convert unmethylated cytosine bases to uracil sulfonate;
b) amplifying the treated DNA with:
i) a primer pair specific for a Septin 9 (SEPT9) gene, wherein the primer pair specific for the SEPT9 gene comprises a first SEPT9 primer comprising SEQ ID NO: 1 and a second SEPT9 primer comprising SEQ ID NO: 2;
ii) a primer pair specific for an Ikaros family zinc-finger 1 (IKZF1) gene, wherein the primer pair specific for the IKZF1 gene comprises a first IKZF1 primer comprising SEQ ID NO: 4 and a second IKZF1 primer comprising SEQ ID NO: 5; and
iii) a primer pair specific for a branched-chain aminotransferase 1 (BCAT1) gene, wherein the primer pair specific for the BCAT1 gene comprises a first BCAT1 primer comprising SEQ ID NO: 7 and a second BCAT1 primer comprising SEQ ID NO: 8; and

c) detecting, using an oligonucleotide probe specific for SEPT9 comprising SEQ ID NO: 3, an oligonucleotide probe specific for IZKF1 comprising SEQ ID NO: 6, and an oligonucleotide probe specific for BCAT1 comprising SEQ ID NO: 9, the methylation status of the SEPT9 gene the IKZF1 gene, and the BCAT1 gene in the cell free biological sample.

2. The method of claim 1 wherein the cell free biological sample is a plasma sample.

3. The method of claim 1 , wherein the cell free biological sample is a stool sample or an enema wash.

4. The method of claim 1 , wherein the neoplasm is a cancer.

5. The method of claim 1 , wherein the neoplasm is an adenoma.

6. The method of claim 1 , wherein the neoplasm is pre-cancerous.

7. The method of claim 1 , wherein said subject is human.

8. The method of claim 1 , wherein the cell free biological sample comprises genomic DNA.

Assignees

• Quest Diagnostics Invest Inc
• Clinical Genomics Pty Ltd

Inventors

• Pedersen Susanne
• Lapointe Lawrence
• Baker Rohan
• Donahue Amber C
• Peng Yen-Lin
• Waldman Frederic

Classifications

• C12Q2600/154

  Methylation markers · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title